The FDA accepts Merck's (MRK -0.5%) NDA for the investigational anti-thrombotic medicine,...


The FDA accepts Merck's (MRK -0.5%) NDA for the investigational anti-thrombotic medicine, vorapaxar for "the secondary prevention of cardiovascular events in patients with a history of heart attack and no history of stroke or transient ischemic attack." The drug has faced an uphill battle since being acquired by MRK in 2009 and, according to Reuters, some analysts question whether bleeding risk will limit its adoption if approved.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs